Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 10/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.48 |
| ▸ | MTOR | P42345 | 8/20 | 0.46 |
| ▸ | RPTOR | Q8N122 | 7/20 | 0.46 |
| ▸ | MLST8 | Q9BVC4 | 7/20 | 0.46 |
| ▸ | RICTOR | Q6R327 | 6/20 | 0.46 |
| ▸ | MAPKAP1 | Q9BPZ7 | 6/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782581 | 1.00 | MAP3K12 (0.49) | MAP3K12PIK3CAMTORRPTORMLST8 | |
| SCHEMBL7763500 | 0.79 | PIK3CA (0.58) | MAP3K12PIK3CAMTORRPTORMLST8 | |
| SCHEMBL7762787 | 0.79 | MTOR (0.53) | MAP3K12PIK3CAMTORRPTORMLST8 | |
| SCHEMBL3772835 | 0.79 | MTOR (0.53) | MAP3K12PIK3CAMTORRPTORMLST8 | |
| SCHEMBL2708158 | 0.78 | MTOR (0.67) | PIK3CAMTORRPTORMLST8RICTOR | |
| SCHEMBL2708152 | 0.78 | MTOR (0.67) | PIK3CAMTORRPTORMLST8RICTOR | |
| SCHEMBL3787795 | 0.78 | MAP3K12 (0.48) | MAP3K12 | |
| SCHEMBL7765699 | 0.78 | MAP3K12 (0.48) | MAP3K12 | |
| SCHEMBL7762788 | 0.76 | MTOR (0.32) | MTOR | |
| SCHEMBL7762925 | 0.73 | PIK3CA (0.48) | MAP3K12PIK3CAMTORRPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151601-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | MAP3K12 40/4885PIK3CA 2/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.